Medicus Pharma Receives FDA Approval To Proceed With Phase 2b Clinical Study Of SkinJect 200 Mcg To Treat Patients With Gorlin Syndrome Presenting With Multiple Basal Cell Carcinomas

Medicus Pharma Q2 EPS $(0.21) Misses $(0.13) Estimate

Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.13) by 61.54 percent. This is a 51.16 percent increase over losses of $(0.43) per share from

Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis

Medicus Pharma Ltd. announced that the UAE Department of Health has granted IND authorization for its PRECISION-E2 Phase 2a clinical study evaluating Teverelix® in women with moderate-to-severe endometriosis. The prospective genomics-guided precision medicine study will enroll approximately 84 women across multiple sites in the UAE and aims to identify biomarkers predicting treatment response to the long-acting GnRH antagonist.

EXCLUSIVE: Medicus Pharma Launches Genomics-Guided Endometriosis Study In Abu Dhabi

Medicus Pharma obtained UAE approval for its PRECISION-E2 Phase 2a clinical trial testing Teverelix in endometriosis patients.

EXCLUSIVE: Medicus Pharma Gets UAE Department of Health Approval for Study of Teverelix in Endometriosis; Phase 2a PRECISION-E2 Study Designed to Evaluate Predefined Panel of Genes to Advance Personalized Medicine